Trastuzumab Deruxtecan biosimilar (Hetero Biopharma)

N/A

Report date: 2025/03/13 16:24:26

Base Information

Drug NameTrastuzumab Deruxtecan biosimilar (Hetero Biopharma)

Drug Alias NameHBP 13

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsDNA topoisomerase I inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeN/A